Final overall survival (OS) results of the feasibility study of adjuvant chemotherapy with docetaxel (DOC) plus cisplatin (CDDP) followed by maintenance chemotherapy of S-1 in completely resected non-small cell lung cancer (NSCLC): Thoracic Oncology Research Group (TORG) 0809

Authors :: Masahiro Tsuboi
Hideki Sakai
Takayuki Kaburagi
Hiroaki Okamoto
Masahiro Takeuchi
Norihiko Ikeda
Seiji Niho
Haruhiro Saito
Kimihiro Shimizu
Koichi Minato
Hideo Kunitoh
Yukio Hosomi
Terufumi Kato
K. Yoshiya
Masanori Tsuchida
Kouichi Suzuki
Hirofumi Michimae
Takashi Seto
Koshiro Watanabe
Source :: Annals of Oncology. 27:vi414
Publication Year :: 2016
Publisher :: Elsevier BV, 2016.

Subjects :: Oncology
Cisplatin
medicine.medical_specialty
business.industry
Adjuvant chemotherapy
non-small cell lung cancer (NSCLC)
Hematology
medicine.disease
Docetaxel
Thoracic Oncology
Internal medicine
Overall survival
Medicine
business
Maintenance chemotherapy
medicine.drug

Full Text Access

Tools